NIOX GroupCSSPF 77 ROC (Joel Greenblatt) % is 231.65% as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 841 Medical Devices & Instruments companies, NIOX Group ranks better than 99.41% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. NIOX Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 231.65%.
The historical rank and industry rank for NIOX Group's ROC (Joel Greenblatt) % or its related term are showing as below:
CSSPF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5107.14 Med: -553.01 Max: 848
Current: 284.75
During the past 13 years, NIOX Group's highest ROC (Joel Greenblatt) % was 848.00%. The lowest was -5107.14%. And the median was -553.01%.
CSSPF's ROC (Joel Greenblatt) % is ranked better than 99.41% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 4.13
vs CSSPF: 284.75
NIOX Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
NIOX Group (OTCPK:CSSPF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
NIOX Group ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for NIOX Group's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, NIOX Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NIOX Group's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 231.65% mean?
NIOX Group (CSSPF) has a ROC (Joel Greenblatt) % of 231.65% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #5 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 0.59999999999999%.
Is NIOX Group's ROC (Joel Greenblatt) % too high?
NIOX Group's current ROC (Joel Greenblatt) % is 231.65%. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.13. NIOX Group's value of 231.65% is 5509% above this industry median. Based on the distribution chart, NIOX Group ranks #5 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #5 out of 841 companies for ROC (Joel Greenblatt) %. This places NIOX Group in the top 1% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.13. NIOX Group's value of 231.65% is 5509% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current ROC (Joel Greenblatt) % of 231.65% is 5509% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current ROC (Joel Greenblatt) % is 231.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current ROC (Joel Greenblatt) % is 231.65% and 5509% above the Medical Devices & Instruments industry median of 4.13. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For NIOX Group (CSSPF), the current ROC (Joel Greenblatt) % is 231.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
ROC (Joel Greenblatt) %: 231.65%
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 5509% above the Medical Devices & Instruments median (#5 of 841)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
